Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-BIA
- Development stage
- Preclinical
- Lead developer
- United States Department of Veterans Affairs
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Oral
01
Overview
7-BIA (7-butoxy illudalic acid analog) is a small molecule inhibitor of receptor-type tyrosine-protein phosphatase delta (PTPRD). Originally identified as a lead compound for the treatment of substance use disorders, particularly cocaine addiction, 7-BIA acts by reducing drug-induced reward effects. PTPRD is a cell-adhesion molecule and synaptic specifier that plays a key role in addiction vulnerability. Beyond addiction, 7-BIA has been investigated for its potential in treating metabolic syndrome and metabolic hypertension. Additionally, recent research has highlighted its role in oncology, where pharmacological inhibition of PTPRD via 7-BIA reverses PTPRD-driven neuronal transdifferentiation and M2 macrophage polarization in TP53-mutant non-small-cell lung cancer (NSCLC), thereby enhancing the efficacy of anti-PD-1 immunotherapy [1.1].
- Other names
- 7-butoxy illudalic acid7-butoxy illudalic acid analog7-butoxy illudalic acid analog 1
02
Targets
PTPN1 (Protein tyrosine phosphatase 1B)PTPRD (Receptor-type tyrosine-protein phosphatase delta)PTPRJ (Protein tyrosine phosphatase receptor type J)PTPRS (Receptor-type protein tyrosine phosphatase sigma)
Beyond the preview
Go deeper on 7-BIA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7-BIA.